Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition that causes persistent airflow limitation and respiratory symptoms such as difficulty breathing, cough, and mucus production, predominantly resulting from smoking, air pollutants, frequent respiratory infections, or untreated asthma. Standard treatments include specific inhalers to help relax and open up the airways.
Health Outcomes
- Absence of Acute Toxicity
- Absence of Treatment-Related Side Effects
- Activation of Nrf2 Pathway
- Additional Therapeutic Benefits
- Alleviated Clinical Outcomes
- Altered Chemokine Response
- Altered Innate Immune Response
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Altered Serum IL-6 Levels
- Association with Sarcopenia
- Beneficial Clinical Effects
- Changed Walking Cadence
- Changes in Inflammatory Markers
- Co-Aggregation with Pathogens
- Confirmed Safety of Treatment
- Decreased FEV1/FVC Ratio
- Decreased IFN-γ Levels
- Decreased Immune Response to Influenza Vaccination
- Decreased Lower Respiratory Quotient
- Decreased Oxygen Saturation
- Decreased Oxygenated Hemoglobin Level
- Delayed Disease Progression
- Delayed Onset of Illness Episode
- Duration of Symptoms
- Efficacy of Postbiotics in Immunocompromised Patients
- Elevated Antipneumococcal IgA Levels in Bronchoalveolar Lavage Fluid
- Elevated IL-6 Levels
- Elevated Interleukin-6 Levels
- Elevated Interleukin-8 Levels
- Elevated Type I IFN Expression in Lung Lymphocytes
- Enhanced Anti-inflammatory Properties
- Enhanced Antioxidant Enzyme Activity
- Enhanced Antioxidant Response
- Enhanced Antipneumococcal IgA Levels in BAL
- Enhanced Goblet Cell Function
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Influenza Resistance
- Enhanced Interferon Gamma Production
- Enhanced Phagocytosis by Monocyte-Derived Dendritic Cells
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Protection Against Influenza Infection
- Enhanced Pulmonary Immune Response
- Enhanced Radical Scavenging Ability
- Enhanced Resistance to Respiratory Infections
- Enhanced Resistance to Streptococcus Pneumoniae Infection
- Enhanced Respiratory Burst Activity
- Enhanced Tolerance Acquisition
- Improved 5000 m Running Time
- Improved 6-Meter Walk Performance
- Improved 6-Minute Walk Test Distance
- Improved 6-minute Walking Distance
- Improved Activities of Daily Living Score
- Improved Aerobic Endurance Performance
- Improved Aerobic Power
- Improved Aerobic Stability
- Improved Airway Immune Response
- Improved Airway Mucosa Condition
- Improved Airway Secretion Clearance
- Improved Anaerobic Threshold
- Improved Antioxidant Capacity
- Improved Antioxidant Defense
- Improved Antioxidant Levels
- Improved Antioxidative Capacity
- Improved Antioxidative Enzyme Activities
- Improved Arterial Oxygen Partial Pressure
- Improved Arterial Oxygen Saturation
- Improved Asthmatic Condition
- Improved Average Power
- Improved Bacterial Viability Under Stress
- Improved Breath Perception
- Improved Cardiopulmonary Exercise Testing
- Improved Catalase Level
- Improved Chest Press Strength
- Improved Clinical Activity
- Improved Clinical Effective Rate
- Improved Clinical Efficacy
- Improved Clinical Outcomes
- Improved Clinical Response
- Improved Clinical Success
- Improved Constant Work Rate Exercise Time
- Improved Consumer Acceptance
- Improved Critical Velocity
- Improved Cycling Endurance
- Improved Cytokine Levels
- Improved Cytoprotection During Oxidative Stress
- Improved Daily Activity Participation
- Improved Deep Lung Delivery Feasibility
- Improved Disease Control
- Improved Disease Management
- Improved Distance Traveled
- Improved Dyspnea
- Improved Effective Rate
- Improved Endurance
- Improved Endurance Exercise Performance
- Improved Endurance Performance
- Improved Endurance Power
- Improved Environmental Stress Tolerance
- Improved Estimated VO2max
- Improved Exercise Capacity
- Improved Exercise Duration
- Improved Exercise Endurance
- Improved Exercise Function
- Improved Exercise Performance
- Improved Exercise Recovery
- Improved Exercise Test Performance
- Improved Exercise Time to Exhaustion
- Improved Exercise Tolerance
- Improved FEV1
- Improved FEV1 Percentage
- Improved FEV1/FVC Ratio
- Improved Fatigue Index
- Improved Fatigue Ratio
- Improved Fatigue Threshold
- Improved Fatigue Tolerance
- Improved Five Times Sit-to-Stand Time
- Improved Forced Expiratory Flow
- Improved Forced Expiratory Volume
- Improved Forced Expiratory Volume in One Second
- Improved Forced Vital Capacity
- Improved Function
- Improved Function Score
- Improved Functional Ability
- Improved Functional Activity
- Improved Functional Capacity
- Improved Functional Exercise Capacity
- Improved Functional Outcome
- Improved Functional Status
- Improved Gain:Feed Ratio
- Improved General Activity
- Improved Global Clinical Status
- Improved Global Evaluation of Patient Scores
- Improved Global Health
- Improved Global Quality of Life
- Improved Global Symptom
- Improved Glutathione Peroxidase Activity
- Improved Glutathione Peroxidase Level
- Improved Glutathione Redox Ratio
- Improved Health Condition
- Improved Health Outcomes
- Improved Health Perception
- Improved Health Status Score
- Improved Health-related Quality of Life
- Improved Histopathological Findings in Lungs
- Improved Hospital Discharge
- Improved Hypoxia Resistance
- Improved Immune Mechanisms Against S. pneumoniae
- Improved Inflammation Homeostasis
- Improved Inflammatory Cytokine Profile
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Response
- Improved Influenza Infection Control
- Improved Inspiratory Muscle Oxygenation
- Improved Intermittent Exercise Performance
- Improved Isokinetic Strength
- Improved JMCIS Score
- Improved Lactate Threshold
- Improved Leg Extension Strength
- Improved Leg Press Performance
- Improved Leukocyte Recruitment
- Improved Lifespan
- Improved Limited Distance Test Performance
- Improved Longevity
- Improved Lower Body Endurance
- Improved Lower Body Muscular Endurance
- Improved Lower Limb Peak Power
- Improved Lower-Body Muscular Strength
- Improved Lung Barrier Function
- Improved Lung Function
- Improved Lung Injury Outcomes
- Improved Maximal Exercise Capacity
- Improved Maximal Inspiratory Pressure
- Improved Maximal Oxygen Capacity
- Improved Maximal Oxygen Consumption
- Improved Maximal Oxygen Uptake
- Improved Maximal Power
- Improved Maximal Walking Performance
- Improved Maximal Workload or Power Output
- Improved Maximum Voluntary Ventilation
- Improved Mean Power Output
- Improved Mucociliary Clearance
- Improved Mucociliary Transportability
- Improved Muscular Endurance
- Improved Neutrophil Function
- Improved Overall Patient Outcomes
- Improved Overall Symptom Relief
- Improved Overall Symptom Score
- Improved Oxidative Status
- Improved Oxidative Stress Levels
- Improved Oxidative Stress Resistance
- Improved Oxidative Stress Tolerance
- Improved Oxygen Saturation
- Improved Oxygenation Index
- Improved Pacing
- Improved Parent/Caregiver Health-Related Quality of Life
- Improved Patient Satisfaction
- Improved Patient-Reported Outcome
- Improved Peak Expiratory Flow
- Improved Peak Oxygen Intake
- Improved Perceived Exertion
- Improved Phagocytic Capacity of Polymorphonuclear Cells
- Improved Phagocytic Function
- Improved Phase Angle
- Improved Physical Activity Initiation
- Improved Physical Activity Level
- Improved Physical Domain Score
- Improved Physical Function
- Improved Physical Health
- Improved Physical Health-Related Quality of Life
- Improved Physical Mobility
- Improved Physical Performance
- Improved Physical Quality of Life
- Improved Physical Role Limitation
- Improved Physical Well-being
- Improved Physical Work Capacity
- Improved Physiological Parameters
- Improved Pneumococcal Infection Outcomes
- Improved Pulmonary Function
- Improved Quadriceps Contraction Strength
- Improved Quadriceps Strength
- Improved Quality of Life
- Improved Quality of Life Score
- Improved Repetitions to Failure
- Improved Resistance to Pneumococcal Respiratory Infection
- Improved Resistance to Secondary Pneumococcal Pneumonia
- Improved Respiratory Disease
- Improved Respiratory Humoral Response
- Improved Respiratory Immune Function
- Improved Respiratory Immunity
- Improved Respiratory Innate Immune Response
- Improved Respiratory Mucosal Barrier Function
- Improved Respiratory Performance
- Improved Respiratory Tract Health
- Improved Role Physical
- Improved Role Physical Health
- Improved Running Endurance
- Improved Running Performance
- Improved Serum Antioxidant Capacity
- Improved Serum Immunity
- Improved Sinonasal Outcome Test Score
- Improved Sit-to-Stand Test Performance
- Improved Six Minute Walking Distance
- Improved Six-Minute Walk Distance
- Improved Six-Minute Walk Test
- Improved Standing Balance
- Improved Survival Rate Against Influenza Virus
- Improved Survival Time
- Improved Swimming Performance
- Improved Symptom Control
- Improved Symptom Relief
- Improved Symptom Severity
- Improved Symptom-Free Status
- Improved Symptoms
- Improved Symptoms of Chronic Condition
- Improved Time to Exhaustion
- Improved Time-Trial Performance
- Improved Timed Up and Go Performance
- Improved Timed Up and Go Test
- Improved Tissue Inhibitor of Matrix Metalloproteinase-1 Level
- Improved Tissue Oxygen Saturation Index
- Improved Tolerance
- Improved Total Antioxidant Status
- Improved Traditional Chinese Medicine Syndrome Effective Rate
- Improved Treatment Compliance
- Improved Treatment Effective Rate
- Improved Treatment Success
- Improved VO2 Max
- Improved VO2max
- Improved Vigor
- Improved Walking Ability
- Improved Walking Distance
- Improved Walking Speed
- Improved Wingate Peak Power
- Improved Work Capacity
- Improved Work Productivity
- Improved Yo-Yo Test Performance
- Incidence of Death
- Increase in Persistent Diseased Sites
- Increased 6-Minute Walk Test Distance
- Increased Abundance of Goblet Cells
- Increased Anti-Inflammatory Cytokine IL-6 Production
- Increased Anti-Pneumococcal Antibody Levels
- Increased Anti-Viral Factor Expression in Lung
- Increased Antibacterial Compound Production
- Increased Bacillus Spore Counts
- Increased Benefit Rate
- Increased Blood Bicarbonate Level
- Increased C-Reactive Protein Levels
- Increased Catalase Activity
- Increased Cytokine Production
- Increased Cytokine Response
- Increased Cytokine Secretion
- Increased Days Alive and Out of Hospital
- Increased Deoxygenated Hemoglobin Level
- Increased Digestible Energy
- Increased Endogenous Acrolein Formation
- Increased Endurance Swimming Time
- Increased Exercise Capacity
- Increased Exercise Endurance
- Increased Expression of CD206
- Increased Expression of Oxidation-Related Gene
- Increased Functional Capacity
- Increased GSH/GSSG Ratio
- Increased General Morbidity
- Increased Glutathione Peroxidase Levels
- Increased Goblet Cell Count
- Increased Goblet Cell Differentiation
- Increased Hospital Admissions
- Increased Hydrogen Peroxide Production
- Increased IFN-γ Concentration
- Increased IL-6 Levels in Early Phase
- Increased IL-8 Levels at 24 Hours
- Increased Incidence of Pulmonary Exacerbations
- Increased Infection Frequency
- Increased Inflammatory Cytokines
- Increased Interleukin 8 Levels
- Increased Interleukin-6 Production in Macrophages
- Increased Invasive Interventions Requirement
- Increased Lactate Production
- Increased Lactic Acid Levels
- Increased Late-Onset Sepsis Incidence
- Increased Length
- Increased Lung CD3+CD4+ IFN-γ+ T Cells
- Increased Malondialdehyde Levels
- Increased Maximal Incremental Cycling Capacity
- Increased MicroRNA-146a Expression
- Increased Monocarboxylic Acid Transporter mRNAs
- Increased Mortality
- Increased Mortality Rate
- Increased Mortality in Patients with Enterococcal Bacteremia
- Increased Mucin Production
- Increased Mucin Secretion
- Increased Mucus Binding Capacity
- Increased Nerve Growth Factor Receptor Level
- Increased Neutrophil Elastase Release
- Increased Neutrophil Oxidative Burst
- Increased Nrf2 Protein Content
- Increased Number of Persistent Diseased Sites
- Increased Oxidative Stress
- Increased Oxygen Consumption
- Increased Oxygen Saturation
- Increased Peak Oxygen Uptake
- Increased Perceived Exertion
- Increased Physical Activity
- Increased Post-Infection Lung Monocyte Levels
- Increased Pro-inflammatory Cytokine IL-6
- Increased Pro-inflammatory Cytokine Production
- Increased Pro-inflammatory Cytokine Release
- Increased Pro-inflammatory Cytokines in Early Healing Phase
- Increased Proportion of Healthy Days
- Increased Protease Levels
- Increased Rating of Perceived Exertion
- Increased Reactive Oxygen Species Production
- Increased Respiratory Burst Activity
- Increased Respiratory Sensitization
- Increased Risk of Opportunistic Pathogenicity
- Increased Satisfaction
- Increased Serum Amyloid Protein
- Increased Serum IL-10 Levels
- Increased Serum Immunoglobulin A (IgA) Levels
- Increased Serum Lysozyme Levels
- Increased Serum Macrophage Inflammatory Protein-1β Levels
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Skin Mucus Protein Levels
- Increased Smoking Cessation Rate
- Increased Superoxide Dismutase Levels
- Increased TIMP-1 Levels
- Increased TNF-α Production
- Increased Time to Ventilatory Threshold
- Increased Total Serum Antioxidant Capacity
- Increased Transforming Growth Factor-β Levels
- Increased Treatment Effectiveness
- Increased Treatment Success Rate
- Increased Tumor Necrosis Factor-Alpha Levels
- Increased VO2 Max
- Increased Viable Cell Antioxidant Activity
- Maintained Beta-Defensin-2 Level
- Maintained Clinical Safety Parameters
- Maintained Physical Activity Level
- Maintained Physical Performance
- Maintenance of NK Cell Activity
- Managed Cystic Fibrosis
- Mitigated Adverse Impacts of IoNPs on Physiological Processes
- Mitigated Adverse Physiological Processes
- Modulated Cytokine Production
- Modulated Inflammatory Cytokine Levels
- Modulated Inflammatory Response
- Modulated Pulmonary Innate Immune Microenvironment
- Modulated Pulmonary Innate Immune Response
- No Change in Anxiety
- No Clear Effect on Depression
- No Difference in Adverse Events
- No Meaningful Change in IL-8
- No Significant Change in Inflammatory Responses
- No Significant Change in Lean Body Mass
- No Significant Impact on Bacterial Community Composition or Diversity
- No Significant Reduction in Lower Respiratory Tract Infections
- Persistent Diseased Sites
- Preserved Anti-pseudomonal Activity
- Prevented Sepsis
- Prevention of Aberrant Inflammatory Response
- Prevention of Mucus Barrier Decline
- Prolonged Survival Time in Influenza Infection
- Reduced 10-meter Walk Test Time
- Reduced 50-Meter Sprint Time
- Reduced Acute Exacerbation Rate
- Reduced Adherence Attrition
- Reduced Adipose Tissue Wasting
- Reduced Airway Inflammation
- Reduced Airway Inflammation Score
- Reduced Airway Pathological Responses
- Reduced Airway Remodeling
- Reduced Alpha-1-Antitrypsin Level
- Reduced BCG Phagocytic Intake
- Reduced Bacterial Infection Severity
- Reduced Bacterial Load in Lungs
- Reduced Bicarbonate Level
- Reduced Body Mass
- Reduced Borg Scale Score
- Reduced COPD-Related Infection
- Reduced Cause-Specific Mortality
- Reduced Cellular Damage
- Reduced Chemokine Production
- Reduced Chronic Obstructive Pulmonary Disease Assessment Test Score
- Reduced Clara Cell Secretory Protein-16 Level
- Reduced Colonization with Multiple Organisms
- Reduced Common Cold Incidence in Susceptible Populations
- Reduced Community Healthcare Costs
- Reduced Composite Symptom Score
- Reduced Concomitant Medication Usage
- Reduced Corticosteroid Usage
- Reduced Cost-Effectiveness in Reducing AAD
- Reduced Cough Frequency
- Reduced Cough Incidence
- Reduced Cough Severity
- Reduced Cough Symptom
- Reduced Coughing Frequency
- Reduced Cumulative Incidents of CIDs in Smokers
- Reduced Cumulative Morbidity Rates
- Reduced Cumulative Mortality
- Reduced Cytokine Response
- Reduced Daily Episode Severity
- Reduced Disability
- Reduced Disease Progression
- Reduced Disease-Related Fatigue
- Reduced Duration of Mechanical Ventilation
- Reduced Dyspnea
- Reduced Dyspnea Score
- Reduced Dyspnea Symptoms
- Reduced Emergency Care Unit Stay Duration
- Reduced Emergency Visit
- Reduced Energy Intake
- Reduced Eosinophil Count
- Reduced Eosinophils in Bronchoalveolar Lavage Fluid
- Reduced Episode Frequency
- Reduced Exacerbation
- Reduced Exacerbation Frequency
- Reduced Exacerbation Rate
- Reduced Exacerbation Risk
- Reduced Exercise Metabolic Intensity
- Reduced Exercise-Induced Biochemical Markers
- Reduced Exertion Perception
- Reduced Exertional Dyspnea
- Reduced Exhaustion
- Reduced Exposure to Harmful Substances
- Reduced Expression of Inflammation-Related Genes
- Reduced Expression of Pro-Inflammatory Cytokines in Lung
- Reduced F2-Isoprostanes
- Reduced FEV1
- Reduced Fatigue Decrement
- Reduced Fatigue Levels
- Reduced Fatigue Severity
- Reduced Forced Expiratory Volume in 1 Second Decline
- Reduced Free Radical Levels
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced Functional Iron Deficiency
- Reduced GAS Adherence to Host Epithelial Cells
- Reduced Glutathione Loss
- Reduced Glutathione Redox Ratio
- Reduced Harmful Bacterial Populations
- Reduced Healthcare Costs
- Reduced Heat Stress
- Reduced Hospital Admission Rate
- Reduced Hospital Readmission Risk
- Reduced Hospital Stay
- Reduced Hospital Stay Duration
- Reduced Hospitalisation
- Reduced Hospitalization
- Reduced Hospitalization Day
- Reduced Hospitalization Duration
- Reduced Hospitalization Frequency
- Reduced Hospitalization Rate
- Reduced Hospitalization Requirement
- Reduced Hyaluronan Level
- Reduced Hypoxia
- Reduced IFN-γ Levels
- Reduced IL-5 Levels
- Reduced IL-6 Secretion
- Reduced IL-8 Production
- Reduced IL-8 Secretion
- Reduced Immune Cell Infiltration
- Reduced Immune Cell Proliferation
- Reduced Immunoinflammatory Markers
- Reduced Impact of Gram-negative Microorganisms
- Reduced In-hospital Mortality
- Reduced Incidence of Bacterial Pneumonia
- Reduced Incidence of Chronic Inflammatory Diseases in Smokers
- Reduced Incidence of Influenza
- Reduced Incidence of Respiratory Illness
- Reduced Incidence of Secondary Bacterial Pneumonia
- Reduced Infection Frequency
- Reduced Inflammation Levels
- Reduced Inflammation in the Lower Respiratory Tract
- Reduced Inflammatory Injury
- Reduced Inflammatory Markers
- Reduced Inflammatory Molecules
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Status
- Reduced Innate Immune Cell Activation
- Reduced Intensive Care Unit Length of Stay
- Reduced Intensive Care Unit Mortality
- Reduced Interference with Daily Life
- Reduced Interferon-Gamma Levels
- Reduced Interleukin-15 Levels
- Reduced Length of Hospitalization
- Reduced Length of Stay
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Life Threatening Complication
- Reduced Lifespan
- Reduced Lifetime Prevalence of Wheeze
- Reduced Lung Damage
- Reduced Lung Function Decline
- Reduced Lung Histopathology Scores
- Reduced Lung Inflammation
- Reduced Lung Injury
- Reduced Lung Neutrophils
- Reduced Lung Tissue Damage
- Reduced MCP-1/CCL2 Levels
- Reduced Malonaldehyde Levels
- Reduced Mechanical Ventilation Requirement
- Reduced Microbial Richness
- Reduced Moraxella Abundance
- Reduced Morbidity Rate
- Reduced Mortality
- Reduced Mortality Rate Before Discharge
- Reduced Mortality from COPD
- Reduced Mortality from Frailty
- Reduced Mortality from Influenza Infection
- Reduced Mucus Secretion
- Reduced Muscle Deoxygenation Rate
- Reduced Muscle Hydration
- Reduced Muscle Protein Breakdown
- Reduced Muscular Endurance
- Reduced NO Secretion Induced by LPS
- Reduced NREM Sleep Quality
- Reduced Nasopharyngeal Moraxella Abundance
- Reduced Non-Programmed Medical Visits
- Reduced Nuclear Factor Erythroid 2-Related Factor 2 Level
- Reduced Nuclear Factor-κB Level
- Reduced Occurrence of Pasty Vent
- Reduced One-Year All-Cause Mortality
- Reduced Opportunistic Pathogens
- Reduced Organ Failure Severity
- Reduced Overall Complication
- Reduced Overall Mortality Rate
- Reduced Overall Symptom Score
- Reduced Oxidative Damage
- Reduced Oxidative Stress
- Reduced Oxidative Stress Score
- Reduced Oxidative Tissue Injury
- Reduced Oxidized Glutathione Level
- Reduced Oxygen Consumption during Exercise
- Reduced Oxygen Saturation Decrease
- Reduced Oxygen Support Requirement
- Reduced PICU Discharge Time
- Reduced Pathogen Adherence
- Reduced Pathogenic Colonies
- Reduced Peak Inspiratory Pressure
- Reduced Phospho-p65 Translocation
- Reduced Physical Activity
- Reduced Physical Fatigue
- Reduced Physical Symptoms
- Reduced Physiological Impairments
- Reduced Plasma Malondialdehyde Levels
- Reduced Pneumococcal Adherence
- Reduced Post-Exercise Lactate Levels
- Reduced Power
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-Inflammatory Fatty Acids
- Reduced Pro-inflammatory Cytokine Level
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Proinflammatory Cytokine Production
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Mediators
- Reduced Proinflammatory Profile
- Reduced Proinflammatory Signaling
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Proportion of Volunteers with At Least One CID
- Reduced Pseudomonas Levels
- Reduced Pseudomonas aeruginosa Infection
- Reduced Pseudomonas aeruginosa-Induced Damage
- Reduced Pulmonary Exacerbation
- Reduced Pulmonary Exacerbations
- Reduced Pulmonary Free-CML
- Reduced Pulmonary Inflammation
- Reduced Quadriceps Muscle Cross-Sectional Area
- Reduced Rating of Perceived Exertion
- Reduced Reactive Oxygen Species Formation
- Reduced Recovery Rate
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Respiratory Burst Activity
- Reduced Respiratory Complications
- Reduced Respiratory Illness
- Reduced Respiratory Inflammation Severity
- Reduced Respiratory Rate
- Reduced Respiratory Symptom Days
- Reduced Respiratory Symptoms
- Reduced Risk of COVID-19 Progression
- Reduced Risk of Prolonged Respiratory Infections
- Reduced Risk of Upper Respiratory Tract Infections
- Reduced Rowing Performance
- Reduced Serious Adverse Events
- Reduced Serum Chemokine Levels
- Reduced Serum IL-6 Levels
- Reduced Serum Inflammatory Cytokines
- Reduced Serum Inflammatory Factors
- Reduced Severity of Acute Respiratory Infection
- Reduced Severity of Influenza Infection
- Reduced Severity of Lung Injuries
- Reduced Severity of Symptoms Per Day
- Reduced Shortness of Breath
- Reduced Significant Weight Loss
- Reduced Sinonasal Outcome Test-22 Score
- Reduced Sputum Elasticity
- Reduced Sputum Severity
- Reduced Sputum Weight
- Reduced Staphylococcus aureus Colonization
- Reduced Steroid Usage
- Reduced Streptococcus pneumoniae in Lung
- Reduced Subjective Symptoms
- Reduced Survival Rate
- Reduced Susceptibility to Pneumococcal Infection
- Reduced Swimming Time
- Reduced Symptom Severity Scale Score
- Reduced T Cell Responsiveness
- Reduced TCM Syndrome Score
- Reduced Thigh Circumference
- Reduced Time Trial Completion Time
- Reduced Time to Complete Uphill Time Trial
- Reduced Timed Up and Go Test Time
- Reduced Tissue Inhibitor of Metalloproteinase 1 Level
- Reduced Total Cells in Bronchoalveolar Lavage Fluid
- Reduced Total Symptom Score
- Reduced Total Time in Bed
- Reduced Transforming Growth Factor Beta Levels
- Reduced Treatment Costs
- Reduced Unplanned Medical Re-presentations
- Reduced Unplanned Re-presentation
- Reduced Upper Respiratory Infections
- Reduced Use of Rescue Medication
- Reduced Virus Titers in Bronchoalveolar Lavage Fluid
- Reduced Walking Time
- Reduced Weight Loss
- Reduced Wheezing
- Regulated Cytokine Levels
- Regulated Inflammation
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Markers
- Regulated Oxidative Stress
- Restored Goblet Cell Function
- Similar Frequency of Adverse Events
- Slower Weight Gain
- Stabilized Disease Progression
- Stable Systemic Inflammatory Response
- Supported Physiological Function in Elderly
- Unchanged Body Composition
- Unchanged Body Weight
- Unchanged IFN-γ Levels
- Unchanged Inflammatory Marker Levels
- Well-Tolerated Long-Term Use